CoLucid to price IPO of 5.36 million shares between $13.00 and $15.00

Piper Jaffray, Stifel, Blair, Ladenburg Thalmann assist with offering

By Devika Patel

Knoxville, Tenn., April 20 – CoLucid Pharmaceuticals, Inc. will sell 5.36 million common shares in its initial public offering with a 30-day greenshoe option of 804,000 additional shares, according to a Form S-1/A filed Monday with the Securities and Exchange Commission. The company has registered up to $92.46 million of stock for the sale, which was announced March 30.

The shares will be sold at a price expected to fall between $13.00 and $15.00 per share.

Piper Jaffray and Stifel are the bookrunning managers. William Blair and Ladenburg Thalmann are the co-managers.

Proceeds will be used for clinical trials, development, working capital, general and administrative expenses and other general corporate purposes.

The biopharmaceutical company is based in Burlington, Mass. The company intends to list its common stock on the Nasdaq under the symbol “CLCD.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.